HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era.

Abstract:

BACKGROUND:No data are available on the clinical presentation and virological pattern in the case of failure of interferon (IFN)-free regimens in patients with genotype-3h. In this paper authors identified the virological and clinical characteristics of patients with genotype-3h treated with suboptimal or not indicated IFN-free regimens for the misclassification of HCV genotype. METHODS:A total of 87 consecutive patients with failure to an IFN-free regimen were re-tested for HCV genotype by HCV NS5B sequencing; the 26 patients identified as harbouring HCV-3 were enrolled. RESULTS:Of the 26 patients enrolled, 4 (15.4%) harboured sub-genotype-3h and 22 (84.6%) 3a. All patients were Italian. Patients with genotype-3a infection were younger (median age 56 years, range 47-78) compared to those with genotype-3h infection (median 74 years, range 65-79; P<0.006). With regard to the failed direct-acting antiviral (DAA)-regimens, three of the four patients with genotype-3h (75%) had been treated with an ineffective​ DAA regimen (paritaprevir, ombitasvir, dasabuvir ± ribavirin for 3 months) more frequently than those with genotype-3a (13.6%; P=0.02), because of previous erroneous identification of HCV-1 genotype. NS5A resistance-associated substitutions (RASs) were observed in 10 (45.4%) genotype-3a-infected patients and in 2 (50%) with genotype-3h. NS5B RASs were observed in only two genotype-3a-infected patients and in none of the 3h-infected patients. CONCLUSIONS:This is the first time genotype-3h has been identified in Italian patients failing an IFN-free regimen, in the majority of cases because of a misclassification of the HCV genotype.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Minichini C,Starace M,De Pascalis S,Macera M,Occhiello L,Caroprese M,Vitrone M,Iovinella V,Guerrera B,Masarone M,Coppola N

doi

10.3851/IMP3228

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

605-609

issue

7

eissn

1359-6535

issn

2040-2058

journal_volume

23

pub_type

杂志文章
  • Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.

    abstract:OBJECTIVES:To evaluate whether fuzzy operators can be usefully applied to the interpretation of genotypic HIV-1 drug resistance by experts, and to improve the prediction of salvage therapy outcome by adapting interpretation rules of genotypic resistance on the basis of their association with virological response data. ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:

    authors: De Luca A,Vendittelli M,Baldini F,Di Giambenedetto S,Trotta MP,Cingolani A,Bacarelli A,Gori C,Perno CF,Antinori A,Ulivi G

    更新日期:2004-08-01 00:00:00

  • Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2.

    abstract:OBJECTIVE:To study decay rates of productively and latently infected cells in peripheral blood and lymph nodes during triple antiretroviral therapy and the possible impact of interleukin-2 (IL-2) on viral kinetics. METHODS:In this non-randomized study, nine antiretroviral-naive HIV-positive patients received either sa...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Stellbrink HJ,Hufert FT,Tenner-Racz K,Lauer J,Schneider C,Albrecht H,Racz P,van Lunzen J

    更新日期:1998-01-01 00:00:00

  • Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina.

    abstract:BACKGROUND:Rilpivirine-based regimens are now preferred or alternative first-line regimens according to many HIV treatment guidelines. Recently, a surveillance study conducted in Argentina determined that prevalence of pretreatment resistance to first-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3147

    authors: Bissio E,Barbás MG,Kademián S,Bouzas MB,Salomón H,Cudolá A,Giuliano SF,Falistocco C

    更新日期:2017-01-01 00:00:00

  • Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.

    abstract:BACKGROUND:A complete virological response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging HBV mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combination therap...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.3851/IMP3169

    authors: Lee SH,Cheon GJ,Kim HS,Kim SG,Kim YS,Jeong SW,Jang JY,Kim BS,Jun BG,Don Kim Y,Jun DW,Sohn JH,Kim TY,Lee BS

    更新日期:2018-01-01 00:00:00

  • Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.

    abstract::Solid organ transplantation in HIV-infected individuals requires concomitant use of immunosuppressants and antiretrovirals that may cause significant drug interactions. Here we report on a peculiar pharmacokinetic interaction between tacrolimus and protease inhibitors (PIs) which occurred in four HIV-infected liver tr...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Pea F,Tavio M,Pavan F,Londero A,Bresadola V,Adani GL,Furlanut M,Viale P

    更新日期:2008-01-01 00:00:00

  • Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.

    abstract::HIV-HBV-coinfected patients require optimal control of viral replication in order to prevent the development of severe comorbidities, such as liver cirrhosis and hepatocellular carcinoma. The genetic diversity of HBV is a poorly investigated factor of such viral replication in HIV-infected hosts. HBV genome diversity ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1495

    authors: Lacombe K,Boyd A,Gozlan J,Lavocat F,Girard PM,Zoulim F

    更新日期:2010-01-01 00:00:00

  • Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.

    abstract:BACKGROUND:This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment. METHODS:A total of 243 patients from Cameroon receiving d4T or zidovudine (AZT) in combination with lamivudine and efavirenz or nevirapine for >6 months were clinically assesse...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1664

    authors: Cournil A,Coudray M,Kouanfack C,Essomba CN,Tonfack CA,Biwolé-Sida M,Delaporte E,Bork K,Laurent C

    更新日期:2010-01-01 00:00:00

  • The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin.

    abstract:BACKGROUND:Ribavirin augments sustained virological response when administered with pegylated interferon for the treatment of chronic HCV infection. The impact of ribavirin plasma concentration on outcome in individuals receiving interferon-free regimens has not been evaluated. METHODS:Stored plasma samples were retri...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2984

    authors: Martinello M,Schteinman A,Alavi M,Williams K,Dore GJ,Day R,Matthews GV

    更新日期:2016-01-01 00:00:00

  • The pathogenesis of liver disease in the setting of HIV-hepatitis B virus coinfection.

    abstract::There are many potential reasons for increased liver-related mortality in HIV-hepatitis B virus (HBV) coinfection compared with either infection alone. HIV infects multiple cells in the liver and might potentially alter the life cycle of HBV, although evidence to date is limited. Unique mutations in HBV have been defi...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Iser DM,Lewin SR

    更新日期:2009-01-01 00:00:00

  • The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.

    abstract:BACKGROUND:Nucleoside (or nucleotide) reverse transcriptase inhibitors (NRTIs) cause side effects in some patients, prompting the use of either partly or fully NRTI-sparing regimens. METHODS:We used data from the Swiss HIV Cohort Study to estimate the effectiveness of two new dolutegravir dual regimens relative to the...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3310

    authors: Young J,Scherrer AU,Calmy A,Tarr PE,Bernasconi E,Cavassini M,Hachfeld A,Vernazza P,Günthard HF,Bucher HC,Swiss HIV Cohort Study.

    更新日期:2019-01-01 00:00:00

  • The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.

    abstract:BACKGROUND:Peripheral neuropathy (PN) in HIV-infected individuals is thought be due to a toxic effect on mitochondria induced by some nucleoside reverse transcriptase inhibitors (NRTI). METHODS:A time-to-event analysis was performed using data from the Delta trial to study the incidence of PN in HIV-infected individua...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:

    authors: Arenas-Pinto A,Bhaskaran K,Dunn D,Weller IV

    更新日期:2008-01-01 00:00:00

  • Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy.

    abstract:BACKGROUND:Little is known about the prognostic factors of acute liver enzyme variations in HIV-hepatitis B virus (HBV)-coinfected patients. OBJECTIVES:To identify prognostic factors of acute liver enzyme abnormalities in HIV-HBV-coinfected patients with a focus on the putative role of antiretroviral drugs. DESIGN:Da...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Chauvel O,Lacombe K,Bonnard P,Lascoux-Combe C,Molina JM,Miailhes P,Girard PM,Carrat F

    更新日期:2007-01-01 00:00:00

  • Smoking motivations and quitting motivations among HIV-infected smokers.

    abstract:BACKGROUND:The aim of this study was to examine smoking motivation and motivation to quit, and determinants of these motivations among HIV-infected cigarette smokers. METHODS:We conducted a 1-day cross-sectional survey on cigarette smoking in a representative sample of HIV-infected outpatients of French hospitals. A c...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1292

    authors: Peretti-Watel P,Garelik D,Baron G,Spire B,Ravaud P,Duval X,EVIT Study Group.

    更新日期:2009-01-01 00:00:00

  • Body image is a major determinant of sexual dysfunction in stable HIV-infected women.

    abstract:BACKGROUND:Prevalence and factors associated with sexual dysfunction in HIV-positive women are poorly known. METHODS:This was a cross-sectional study in a cohort of HIV-infected women. Clinically stable women were invited to participate in a female sexual dysfunction (FSD) evaluation with Female Sexual Function Index ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Luzi K,Guaraldi G,Murri R,De Paola M,Orlando G,Squillace N,Esposito R,Rochira V,Zirilli L,Martinez E

    更新日期:2009-01-01 00:00:00

  • In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.

    abstract:BACKGROUND:In vitro studies have reported controversial effects of protease inhibitors (PIs) on mitochondrially driven apoptosis. Additionally, since PIs in the clinical setting are almost always given in combination with nucleoside analogues, which may have negative effects on mitochondrial DNA (mtDNA), the impact of ...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Miró O,Villarroya J,Garrabou G,López S,Rodríguez de la Concepción M,Pedrol E,Martínez E,Giralt M,Gatell JM,Cardellach F,Casademont J,Villarroya F

    更新日期:2005-01-01 00:00:00

  • Acute renal failure related to high doses of acyclovir (15 mg/kg/8 h) during treatment of varicella zoster virus encephalitis.

    abstract::Varicella zoster virus (VZV) is less susceptible than herpes simplex virus to acyclovir. The optimal acyclovir regimen during VZV encephalitis remains unknown. We report two cases of acute renal failure after an increase in acyclovir dosage from 10 mg to 15 mg/kg/8 h during the treatment of VZV encephalitis according ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3313

    authors: Martinot M,Klein A,Demesmay K,Groza M,Mohseni-Zadeh M,Tebacher-Alt M,Fafi-Kremer S

    更新日期:2019-01-01 00:00:00

  • Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.

    abstract:BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.3851/IMP2358

    authors: Vingerhoets J,Rimsky L,Van Eygen V,Nijs S,Vanveggel S,Boven K,Picchio G

    更新日期:2013-01-01 00:00:00

  • Biphasic pattern of depression and its predictors during pegylated interferon-based therapy in chronic hepatitis B and C patients.

    abstract:BACKGROUND:It remains unclear whether depression in chronic hepatitis B (CHB) and chronic hepatitis C (CHC) during pegylated interferon-based therapy is associated with the virus, drug or ethnic background. We aimed to perform a prospective study to evaluate the clinical course of depression and its predictors in conse...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2441

    authors: Huang YW,Hu JT,Hu FC,Chang CJ,Chang HY,Kao JH,Yang SS,Chen DS

    更新日期:2013-01-01 00:00:00

  • Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV.

    abstract:BACKGROUND:Monocytes transmigrating to the brain play a central role in HIV neuropathology. We hypothesized that the continued existence of neurocognitive impairment (NCI) despite potent antiretroviral (ARV) therapy is mediated by the inability of such therapy to control this monocyte/macrophage reservoir. METHODS:Cro...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2411

    authors: Shikuma CM,Nakamoto B,Shiramizu B,Liang CY,DeGruttola V,Bennett K,Paul R,Kallianpur K,Chow D,Gavegnano C,Hurwitz SJ,Schinazi RF,Valcour VG

    更新日期:2012-01-01 00:00:00

  • Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.

    abstract:BACKGROUND:Voxilaprevir (VOX; GS-9857) is a pangenotypic HCV NS3/4A protease inhibitor (PI) with potent antiviral activity against HCV genotypes (GTs) 1-6 and improved coverage of GT1 NS3 resistance-associated substitutions (RAS) associated with other HCV PIs. In a 3-day Phase Ib monotherapy study in patients infected ...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.3851/IMP3202

    authors: Lawitz E,Yang JC,Stamm LM,Taylor JG,Cheng G,Brainard DM,Miller MD,Mo H,Dvory-Sobol H

    更新日期:2018-01-01 00:00:00

  • K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

    abstract::Antiretroviral treatment with three nucleoside reverse transcriptase inhibitors (NRTIs) is widely used, but the combination of abacavir, didanosine and stavudine has never been investigated. We describe the surprising and consistent genotypic and phenotypic outcome in patients failing this combination. As part of a Da...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Røge BT,Katzenstein TL,Obel N,Nielsen H,Kirk O,Pedersen C,Mathiesen L,Lundgren J,Gerstoft J

    更新日期:2003-04-01 00:00:00

  • Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.

    abstract:BACKGROUND:Alternatives to the available stavudine-containing paediatric fixed-dose combination (FDC) tablets are rapidly needed due to concerns regarding the cumulative toxicity of long-term stavudine exposure. We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lam...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3851/IMP1931

    authors: Chokephaibulkit K,Cressey TR,Capparelli E,Sirisanthana V,Muresan P,Hongsiriwon S,Ngampiyaskul C,Limwongse C,Wittawatmongkol O,Aurpibul L,Kabat B,Toye M,Smith ME,Eksaengsri A,McIntosh K,Yogev R,IMPAACT P1069 Team.

    更新日期:2011-01-01 00:00:00

  • Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.

    abstract::We assessed the prevalence and clinical impact of insertions within the HIV-1 p6Gag proline-rich (PTAP) region on initial antiretroviral therapy response in 461 HIV-infected, drug-naive individuals initiating therapy in British Columbia, Canada between June 1996 and August 1998. HIV p6Gag insertions were detected by n...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Brumme ZL,Chan KJ,Dong WW,Wynhoven B,Mo T,Hogg RS,Montaner JS,O'Shaughnessy MV,Harrigan PR

    更新日期:2003-04-01 00:00:00

  • Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.

    abstract:BACKGROUND:Neuraminidase (NA) inhibitors (NAIs), including oseltamivir and zanamivir, play an important therapeutic role against influenza infections in immunocompromised patients. In such settings, however, NAI therapy may lead to the emergence of resistance involving mutations within the influenza surface genes. The ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3344

    authors: Abed Y,Schibler M,Checkmahomed L,Carbonneau J,Venable MC,Fage C,Giannotti F,Goncalves AR,Kaiser L,Boivin G

    更新日期:2019-01-01 00:00:00

  • Does antiviral therapy prevent hepatocellular carcinoma?

    abstract::Chronic infection with HBV or HCV can lead to the development of hepatocellular carcinoma (HCC). The major risk factors for HBV-related HCC are persistent presence of hepatitis B e antigen (HBeAg) and/or high serum HBV DNA levels, and cirrhosis. The major risk factor for HCV-related HCC is cirrhosis. One randomized do...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1895

    authors: Kwon H,Lok AS

    更新日期:2011-01-01 00:00:00

  • Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.

    abstract:OBJECTIVE:To estimate the treatment and health care costs of HIV infection or AIDS in France during the era of highly active antiretroviral therapy (HAART). DESIGN:We used a clinical database of HIV-infected patients to calculate the resource use and cost of care for different stages of HIV infection. Costs were incor...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Yazdanpanah Y,Goldie SJ,Losina E,Weinstein MC,Lebrun T,Paltiel AD,Seage GR 3rd,Leblanc G,Ajana F,Kimmel AD,Zhang H,Salamon R,Mouton Y,Freedberg KA

    更新日期:2002-12-01 00:00:00

  • Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection.

    abstract:BACKGROUND:IL28B genotype predicts response to treatment against HCV with pegylated interferon/ribavirin (PR) and impacts on the outcome of therapy including telaprevir (TVR). This study aimed to determine the influence of the favourable IL28B genotype on early viral kinetics during therapy with TVR/PR in HIV-HCV-coinf...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP2921

    authors: Neukam K,Munteanu D,Haubitz S,Mira JA,Ingiliz P,Rivero-Juárez A,Lutz T,de los Santos-Gil I,Scholten S,Márquez M,Rauch A,Rockstroh JK,Pineda JA

    更新日期:2015-01-01 00:00:00

  • Health economics in HIV disease.

    abstract::All illnesses and, by association, all provision of health care in any setting have a cost, whether it is the direct cost to the consumer, to the provider (for example, a national health service) or the indirect cost to an employer or to society in lost production. Disease also has hidden or intangible costs of pain, ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Youle M

    更新日期:1999-01-01 00:00:00

  • Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus.

    abstract::A novel severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) has been identified as the aetiological agent of SARS. We previously isolated and characterized SARS-CoV and SARS-CoV-like viruses from human and animals, respectively, suggesting that SARS could be transmitted from wild/farmed animals ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Zheng BJ,Guan Y,Hez ML,Sun H,Du L,Zheng Y,Wong KL,Chen H,Chen Y,Lu L,Tanner JA,Watt RM,Niccolai N,Bernini A,Spiga O,Woo PC,Kung HF,Yuen KY,Huang JD

    更新日期:2005-01-01 00:00:00

  • Maternal antiretroviral prophylaxis and breastfeeding.

    abstract::The prevention of mother-to-child transmission of HIV-1 during breastfeeding is a major concern in resource-poor settings where alternatives to breast milk may be unaffordable, unsafe and limited by social stigma. The use of triple-drug antiretroviral regimens initiated during pregnancy and continued throughout breast...

    journal_title:Antiviral therapy

    pub_type: 评论,杂志文章

    doi:10.3851/IMP2314

    authors: Marzolini C,Gray GE

    更新日期:2012-01-01 00:00:00